1. Introduction {#s0010}
===============

The human gastrointestinal (GI) tract has coevolved with billions of commensal microorganisms that are considered by many immunologists to be an "extended self" ([@bb0350]). This symbiotic relationship between microorganisms and the host requires efficient barrier and tolerance mechanisms that preserve intestinal immune balance and tissue integrity. HIV infection leads to disruption of both immune balance and epithelial barrier integrity, contributing to residual immune activation ([@bb0470]). Such immune activation persists despite ART and is associated with an increased risk of non-AIDS morbidities, such as cardiovascular diseases and neurocognitive disorders. This persistent immune activation is thought to originate from latently infected cells contributing to residual HIV expression, and gut barrier damage. Cumulative evidence indicates that multiple events occur within the GI tract of pathogenically Simian Immunodeficiency Virus (SIV)-infected Asian macaques and HIV-infected individuals ([@bb0140], [@bb0050]). These events cause increased intestinal permeability, resulting in the translocation of bacterial products of the GI microflora through the epithelial barrier and into the systemic circulation. This microbial translocation is considered to be a major driver of chronic immune activation and disease progression, even in patients receiving ART ([@bb0055], [@bb0445]).

Our understanding of SIV- and HIV-induced immune gut damage was primarily based on CD4 T cell studies, with changes in CD8 T cells and myeloid populations being relatively less studied. Herein, we highlight the key findings of gut mucosa studies of SIV-infected rhesus macaques (RMs) and HIV-infected subjects that have revealed changes in the distribution of Th17, Treg, Th22, CD8 T cells, innate lymphoid cells and myeloid cells, in addition to the disruption of the local cytokine/chemokine network. We also review studies describing SIV/HIV-induced injuries to the intestinal epithelium, changes in the composition of the gut microbiota, and/or translocation of gut microbial products. Our findings underline the importance of designing novel therapies that target microbial composition and gut barrier integrity to further control immune activation that in turn will improve the quality of life of HIV-infected individuals, while potentially reducing the size of the HIV reservoir.

2. Gut Damage in Conditions Other Than HIV: Learning From "Outside the Box" {#s0015}
===========================================================================

Early in the HIV pandemic, GI dysfunctions were reported in patients progressing to AIDS. These dysfunctions included nutrient malabsorption, diarrhea and weight loss, all of which pointed to a link between the disruption of immune homeostasis and gut damage ([@bb0215]). Initial descriptions of the pathological changes observed in patients with advanced HIV infection evoked GI manifestations of Crohn\'s disease and ulcerative colitis, two major forms of inflammatory bowel disease (IBD), ([@bb0175]). Both IBD and HIV infections can be considered as conditions involving a breakage in the mutualism between the host and the gut microbiota. Graft-versus-host disease (GVHD) is also characterized by features of gut damage including immunosuppression, alteration of the composition of the intestinal microbiota, and microbial translocation, all of which lead to systemic inflammation ([@bb0185]).

These findings raise questions regarding the determinants of immune tolerance towards the intestinal microbiota. Due to limitations in assessing mucosal immune responses in patients, non-human primate (NHP) models of SIV-related gut damage have played a critical role in understanding the interplay between microbiota, gut barrier integrity and systemic immune responses. In this review, we synthesize the studies of mucosal immunity in NHP models and discuss their relevance to HIV pathogenesis.

3. Gut Damage in SIV Infection: A Mucosal Tragedy {#s0210}
=================================================

3.1. Non-human Primate Models of HIV/AIDS {#s0025}
-----------------------------------------

Macaques that develop an AIDS-like disease following experimental SIV infection include rhesus (*Macaca mulatta*), cynomolgus (*Macaca fascicularis*), and pigtail (*Macaca nemestrina*) macaques. The RM model is the most extensively studied and includes the Indian and Chinese subtypes; the Indian subtype experiences faster disease progression compared to the Chinese subspecie (reviewed in [@bb0485]). In contrast to progressive SIV infection of Asian macaques, over 40 known species of African non-human primates are endemically infected ([@bb0085]). These natural hosts of SIV, which remain asymptomatic, are characterized by a low level of immune activation despite highly replicating virus. Among these species, sooty mangabeys (SMs) and African green monkeys (AGMs) have been extensively studied as nonpathogenic models. Progressive and nonpathogenic models have contributed to our understanding of mucosal immunity and immune activation during SIV infection.

The gut mucosal immune system of NHP and humans is divided into inducible and effector compartments. The inducible sites are composed of organized lymphoid structures such as Peyer\'s patches and isolated lymphoid follicles ([@bb0045]). The effector sites, comprised of the epithelium lining the gut lumen and the subjacent *lamina propria* (LP), contain diffusely distributed myeloid and lymphoid cells.

3.2. CD4 T Cell Depletion: Targeting the "Helpers" {#s0030}
--------------------------------------------------

Mucosal CD4 T cell depletion was first reported in AIDS patients; this depletion was predominant in the duodenum ([@bb0355]), suggesting differential impact of HIV infection along the intestine. CD4 T cell changes in early SIV infection were subsequently investigated in NHP models; key study findings are summarized in [Table 1](#t0005){ref-type="table"}. In Indian RMs, enteropathies were reported by Veazey et al. who observed the depletion of 80% to 90% of activated CD4 T cells in the gut mucosa at day 14 post-infection ([@bb0425]). In Chinese RMs, rectal CD4^+^ T cells were depleted by 30% at day 14 post-infection, although no changes were observed in the small intestine ([@bb0105]). In these studies, mucosal helper T cell depletion was assessed by measuring CD4 T cell frequencies, which is influenced by the size of other cell populations. Therefore, immunostaining was performed in subsequent studies. The colon of Indian RMs showed up to 50% depletion of CD4 T cells ([@bb0235]); in newly HIV-infected individuals, CD4 T cell depletion was detected in the effector sites of the rectal mucosa although the authors reported that it was difficult to precisely quantify T cell numbers in small biopsies ([@bb0275]). In contrast, no change was observed in the duodenum during acute HIV infection ([@bb0010]) and in the ileum of acutely SIV-infected Chinese RMs ([@bb0330]), suggesting that a reduction in the absolute numbers of CD4 T cells may be less dramatic during very early HIV infection and less pathogenic SIV model. The key findings that examined the effect of HIV on gut CD4 T cell numbers are summarized in [Table 2](#t0010){ref-type="table"}.

Most of the CD4 T cells depleted by SIV/HIV are memory cells that express CCR5, one of the main co-receptors for SIV/HIV entry ([@bb0270]). Functional studies have shown the impairment of Th17 and Th22 subsets involved in the maintenance of gut barrier integrity in both acute ([@bb0315]) and chronic SIV/HIV infections ([@bb0205], [@bb0110], [@bb0455]). The loss of intestinal CD4 T cells was also reported in nonpathogenic SIV infections, although Th17 subsets in the LP were preserved ([@bb0085]). In addition, a transient loss of mucosal Foxp3^+^ Treg was observed in the pathogenic SIV infection of pigtail macaques ([@bb0145]) and RMs ([@bb0295]); these cells were not lost in AGMs, which are natural SIV hosts, demonstrating that an altered Th17/Treg ratio characterizes pathogenic SIV infection. In chronic HIV infection, Th17 cells were massively depleted while Treg frequency increased in the gut mucosa ([@bb0380], [@bb0135]). Overall, these results show that impairment of intestinal Th17/Th22 cells is associated with systemic immune activation, shedding light on the importance of the gut damage that occurs in early HIV infection.

3.3. The CD8 T Cell Compartment: Under the Shadow of the Almighty CD4 T Cells? {#s0035}
------------------------------------------------------------------------------

Most studies of SIV/HIV-induced gut damage have focused on T helper cells. Increasing evidence highlights the importance of the CD8 T cell compartment in SIV/HIV disease progression ([Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}). An increased frequency of persistent, circulating CD8 T cells is associated with a higher risk of non-AIDS events ([@bb0290]). Several studies have demonstrated that CD8 T cell infiltration of the intestine is linked to memory CD4 T cell depletion in acute SIV infection of RMs ([@bb0420]), ([@bb0270]), ([@bb0450]). During acute SIV infection of Chinese RMs, we observed in the ileum LP an increase of CD8 T cell numbers concomitant with enhanced expression of T cell attracting chemokines, associated with a transient decrease in circulating CD8 T cells ([@bb0330]). These results suggest that a shift in circulating CD8 T cell homing to the gut mucosa had occurred. In addition, the colon of acutely SIV-infected RMs was characterized by perforin overexpression, suggesting a strong cytotoxic response during early infection ([@bb0335]). In chronic SIV infection, the presence of specific cytotoxic T cells in the intestine correlated with preserved CD4 T cell counts ([@bb0370]), highlighting the role of the CD8 T cell specific immune response in maintaining mucosal integrity.

An expansion of total CD8 T cells was also reported in the rectal mucosa of SIV-infected RMs; upon further investigation, it was demonstrated that increased numbers of CD8 Treg (CD8^+^ FOXP3^+^) persisted during chronic SIV infection ([@bb0295]). Although CD4 Th17 cells are considered to be the main source of interleukin (IL)-17 and IL-22, recent studies have revealed that Tc17 cells, a subset of CD8 T cells that produce IL-17, are maintained in the gut of RMs during acute SIV infection and are progressively depleted during the chronic stage ([@bb0300]), ([@bb0460]). These results indicate that, in addition to the CD4 Th17/Treg ratio, an altered balance between Tc17 cells and CD8 Treg characterizes progressive SIV and HIV infections.

3.4. Intestinal Innate Immune Cell Dysfunction in SIV/HIV Infection: Disturbed Crosstalk Between Innate and Adaptive Immunity {#s0040}
-----------------------------------------------------------------------------------------------------------------------------

### 3.4.1. Innate Lymphoid Cells: New Players in the Field of Gut Damage {#s0045}

Innate lymphoid cells (ILCs) are a growing group of immune cells enriched at mucosal surfaces that mirror the phenotypes and functions of T cells ([@bb0125]). Conversely to T cells, ILCs do not express acquired antigen receptors or undergo clonal selection and expansion upon stimulation. Instead, ILCs react promptly to signals from infected tissues by secreting cytokines. ILCs have been classified into three main types based upon their cytokine responses and transcription factors that regulate their function. Type 1 ILCs (ILC1) secrete Th1-related cytokines such as interferon-γ (IFN-γ) and tumor necrosis factor alpha (TNF-α) and promote immunity against intracellular pathogens. ILC2 produce type 2 cytokines (IL-4, IL-5) and play a significant role in response to helminth infection. ILC3 produce IL-17 and IL-22 and express the transcription factor RORγt, ([@bb0405]). Thus, ILC3 share effector functions with Th17 cells, although performing their functions in the absence of antigen specificity ([@bb0015]). Convergent study findings of Indian RM have shown that IL-17-producing ILCs are rapidly and persistently depleted in the GI tract following SIV infection ([@bb0460], [@bb0250], [@bb0465]). Xu et al. identified translocated microbial products as a driver of ILC apoptosis through TLR-mediated signaling. Furthermore, both colonic and circulating blood ILC3 are decreased in HIV-infected individuals and predict disease progression ([@bb0475]). The identification of ILCs represents a paradigm shift in mucosal immunology as these cells established a bridge between microenvironment and adaptive immunity and are severely damaged during SIV/HIV infections.

### 3.4.2. Intestinal Macrophages: Supplanting the Silent Sentinels {#s0050}

Intestinal macrophages are strategically located in the LP lining the epithelium. These cells can efficiently perform phagocytic and bactericidal functions without inducing inflammation ([@bb0390]). In healthy gut mucosa, macrophages express toll like receptor-4 (TLR-4), do not express CD14, the co-receptor for gram-negative bacteria lipopolysaccharide (LPS), and do not produce inflammatory cytokines such as TNF-α, IL-6 or CXCL10 ([@bb0395]). Therefore, gut macrophages are critical for protecting epithelium integrity. These cells also express low levels of CD4 and of the HIV co-receptors CCR5 and CXCR4, thereby reducing their susceptibility to HIV infection, and do not seem to support HIV replication ([@bb0385]).

Numerous studies have observed that SIV and HIV induce intestinal myeloid cell dysfunction, depicted in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, respectively. Gut macrophages with defective phagocytic function were observed by Estes et al. in chronically, but not acutely, SIV-infected Indian RMs ([@bb0140]). This observation could explain the limited microbial translocation observed in acute SIV/HIV infections during which time gut macrophages are still capable of effectively phagocytosing microbial products.

As intestinal resident macrophages have reduced proliferative capacity, the recruitment of circulating monocytes is likely the main source for their renewal. While the pro-inflammatory CD16^+^ monocyte subset is expanded in SIV-infected RMs, the number of these cells remains stable in nonpathogenic infection of SMs. These observations suggest that CD16^+^ monocytes contribute to SIV/HIV pathogenesis. In chronically HIV-infected individuals, inflammatory monocytes accumulate in the LP of the duodenum in response to increased mucosal levels of the CCL2 chemokine ([@bb0005]). Furthermore, CD14^+^ macrophages accumulate in the colon of AIDS patients and correlate with the degree of microbial translocation ([@bb0080]).

Collectively, these observations indicate that the infiltration of pro-inflammatory monocytes into the intestinal mucosa during SIV/HIV infections, which results in the development of tissue-resident macrophages, promotes local inflammation and tissue injury; this process results in further recruitment of circulating monocytes. Moreover, the low phagocytic activity of the resulting macrophages prevents efficient purging of microbial products, resulting in increased microbial translocation across the injured intestinal barrier.

### 3.4.3. Neutrophil and Dendritic Cell Contribution to Gut Damage {#s0055}

Among the other immune cells in the gut mucosa are polymorphonuclear neutrophils (PMNs) and dendritic cells (DCs), whose contributions to gut damage in SIV/HIV infections have not been well studied. The results of studies that have been performed are summarized in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}.

PMNs contribute to the first line of defense against bacterial and fungal pathogens. These cells rapidly migrate to the inflamed tissues where their activation triggers the release of antimicrobial peptides and proteolytic enzymes such as myeloperoxidase. During chronic SIV infection of RMs, neutrophils, which were shown to have infiltrated the colonic mucosa, were linked to epithelial barrier damage ([@bb0140]). Neutrophils were also reported to have invaded the rectal mucosa of RM four weeks after SIV infection ([@bb0315]). In contrast, Hensley-McBain et al. did not report increased PMN counts within the first 28 days following SIV infection of RMs, which was likely due to a lack of PMN-supporting cytokines ([@bb0165]). Furthermore, circulating neutrophils are more prone to undergo apoptosis during pathogenic SIV infection as compared to nonpathogenic models ([@bb0130]). Therefore, while the virus itself may not induce PMN accumulation during early infection, some lines of evidence point to PMN infiltration during chronic SIV/HIV infections, suggesting that PMNs might contribute to inflammation and gut barrier damage during the chronic phase.

In contrast to neutrophils, which are recruited by the inflamed mucosa, DCs are resident cells that are diffusely located throughout the LP, within Peyer\'s patches and in isolated lymphoid follicles. Intestinal DCs include CD123^+^ plasmacytoid DCs (pDCs) and CD11c^+^ myeloid-derived DCs (mDCs). pDCs are a major source of IFN-α, providing a first line of defense against HIV ([@bb0060]). Studies of SIV infection have demonstrated that IFN-α and TNF-α producing pDCs accumulate in the gut mucosa and participate in the ongoing immune activation instead of controlling initial SIV dissemination ([@bb0255], [@bb0345]). In another study, a subset of DCs that expressed CD103 (integrin αE), was found to be depleted in the colon, while no change was observed in mDC or pDC frequencies ([@bb0205]). These contrasting results highlight the need to clarify the contribution of DCs to the gut mucosal inflammation that occurs during SIV infection.

3.5. Altered Chemokine/Cytokine Microenvironment: Do Recruited Soldiers Become Prey for SIV/HIV? {#s0060}
------------------------------------------------------------------------------------------------

Numerous studies have shown that intestinal tissues exhibit altered chemokine and cytokine networks due to SIV infection; the results of these studies are summarized in [Table 3](#t0015){ref-type="table"}. CCL20 and CCL21 chemokines associated with the trafficking of DCs, B and T cells are unchanged during the course of SIV infection ([@bb0090]), while CCL19 and CXCL9 are up-regulated in the small intestine of RMs during acute infection and are associated with the recruitment of CD4 T cells ([@bb0100]), potentially feeding viral replication. Tissue CD8 T cell counts increase during SIV infection and these cells secrete CCL5 (a CCR5 ligand) and GM-CSF into the small intestine ([@bb0190]), suggesting that DCs, monocytes/macrophages, T cells, B cells, as well as neutrophils, could be rapidly recruited to the gut. Importantly, increased expression of CCL5 could be implicated in the exacerbation of HIV pathogenesis ([@bb0480]). We have also evidenced enhanced expression of gut-expressed CCL25, which recruits CCR9^+^ effector T cells, and IFN-γ induced CXCL10, which has the potential to attract monocytes/macrophages, DCs, and T and B cells, in acute SIV infection of RMs ([@bb0330]).

Furthermore, several studies have demonstrated increased levels of pro-inflammatory cytokines such as IL-1β, TNF-α, IFN-α, IFN-γ, IL-8 and IL-17 in the gut mucosa following SIV infection. Increased levels of immunomodulatory IL-10 ([@bb0320]) and transforming growth factor beta (TGF-β), ([@bb0340]) are also observed in SIV infection, suggesting that these cytokines were not able to induce anti-inflammatory responses. Importantly, in experimental SIV infection of SM and AGM natural hosts, the evaluation of plasma cytokine levels in early infection showed that the absence of immune activation was due to a significant downregulation of inflammatory cytokines rather than a lack of early inflammation ([@bb0325]).

3.6. Structural Gut Damage Causes Leakage of a Modified Gut Microbiota {#s0065}
----------------------------------------------------------------------

### 3.6.1. Epithelial Barrier Disruption: Creating Breaches for Microbial Invaders {#s0070}

The intestinal epithelium, made of a single layer of enterocytes together with a luminal mucus layer, provides a physical and chemical barrier between the host and the so-called "extended-self" luminal microbiome. The chemical barrier includes soluble factors such as IgA and defensins. Epithelial cells establish close contact at their lateral cell membranes by dynamic structures named tight junctions, which interconnect the cells and restrict the passage of bacterial products through the paracellular space. Intestinal epithelial cells express the IL-22 receptor, which plays an important role in the renewal of the gut barrier ([@bb0025]).

Damage to the gut barrier involves the apoptosis of enterocytes during the acute stage of SIV infection, which persists in the chronic phase ([@bb0240], [@bb0320]). Li et al. reported massive SIV-induced epithelial cell apoptosis as an underlying mechanism of the regenerative enteropathy that characterizes early SIV infection. Consistently, another study described enhanced epithelial cell proliferation during SIV infection, as a repair mechanism triggered in response to massive enterocyte death ([@bb0285]). In contrast, impaired epithelial proliferation, which was detected in the colorectal tissues of HIV-infected patients, was linked to increased apoptosis ([@bb0400]). Therefore, it remains unclear whether mucosal apoptosis in ART-treated individuals is a cause or a consequence of epithelial proliferative changes. Moreover, the rapid, SIV-induced secretion of IL-1β correlated with decreased expression and with mislocalization of tight junction proteins ([@bb0170]).

Thus, during SIV/HIV infections, damage to the physical integrity of the epithelium causes breaches in the gut barrier that increases intestinal tract permeability, resulting in the passage of luminal microbiota products through the mucosa into the systemic circulation ([@bb0140]).

### 3.6.2. Microbiota Changes and Inflammation Throughout the Gut Barrier: A Two-way Street {#s0075}

Studies of untreated HIV-infected individuals have revealed altered composition of the fecal microbiota in which pathogenic bacteria such as proteobacteria species were found at higher levels than probiotics such as *Lactobacilli* ([@bb0150]); this flora modification persisted during short-term ART ([@bb0305]). Furthermore, several groups have reported an altered *Bacteroides*/*Prevotella* ratio in untreated HIV-infected persons ([@bb0260]), detected in gut epithelium adherent microbiota ([@bb0115]). Dysbiosis of the gut microbiota and changes in their dietary tryptophan catabolite by-products were associated with mucosal and systemic immune activation, contributing to disease progression ([@bb0435], [@bb0115], [@bb0360]), suggesting that gut-resident microbial communities influence HIV pathogenesis. NHP models, which have permitted the longitudinal sampling of feces throughout SIV infection, have diminished the bias attributed to differences in diet. In contrast to findings in human studies, SIV infection did not cause significant alterations of the fecal and gut-associated bacteriome ([@bb0155]), with dysbiosis, characterized by an enrichment of proteobacteria that may preferentially translocate, observed only in ART-treated macaques ([@bb0195]). However, a recent study of untreated acute SIV infection of RMs demonstrated specific depletion of *Lactobacilli*, supporting previous findings in HIV-infected persons ([@bb0440]). This diminution of *Lactobacilli* was associated with increased activity of the tryptophan-catabolizing immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1) and with Th17 loss, suggesting that *Lactobacillus* species inhibit IDO1 activity as a mechanism to maintain mucosal immune homeostasis. Importantly, these results highlight the need for new therapeutic strategies to regulate both metabolic activity and composition of the intestinal flora.

### 3.6.3. Microbial Translocation and Biomarkers of Gut Damage {#s0080}

SIV-induced gut damage and subsequent microbial translocation have been linked for the first time to systemic immune activation in chronically SIV-infected Indian RMs ([@bb0055], [@bb0140]). In these seminal studies, plasmatic bacterial LPS levels correlated with activation markers such as T cell CD38 and HLA-DR, and with plasma soluble CD14 (sCD14), which is released by activated monocytes. The effect of gut damage and microbial translocation on pathogenic immune activation was demonstrated in uninfected pigtail macaques ([@bb0200]) and in experimentally-induced colitis in RMs ([@bb0160]). This latter study demonstrated the value of a non-invasive clinical monitoring technique to assess intestinal microvasculature leakage in IBD and HIV patients. Furthermore, early HIV infection has been associated with higher levels of LPS-binding protein (LBP) and with intestinal fatty acid binding protein (I-FABP), a marker of enterocyte damage ([@bb0265]).

Clearly, numerous complex mechanisms contribute to gut damage that occurs following SIV/HIV infections (summarized in [Fig. 1](#f0005){ref-type="fig"}). We propose that therapies targeting the composition and metabolic activity of the GI microbiota, which are altered in HIV-infected individuals, could benefit ART-treated individuals.

4. Strategies to Restore the Integrity of the Gut Barrier {#s0085}
=========================================================

4.1. Early ART is Not Sufficient to Fully Restore Gut Damage {#s0090}
------------------------------------------------------------

We have previously reviewed the results of several clinical trials that investigated the effect of early ART on gut dysfunction ([@bb0075]). Importantly, early ART initiation preserved Th17 function and reversed immune activation, as defined by the expression of the T cell activation markers CD38 and HLA-DR. However, gut damage, which was assessed by measuring plasma I-FABP and LPS levels, was not reversed by early ART, suggesting ongoing enterocyte damage and subsequent bacterial translocation ([@bb0180]). We and others have reported that initiation of ART during acute infection preserved mucosal CD4 T cells without reducing CD8 T cell infiltration ([@bb0010], [@bb0070]). These data indicate that mucosal damage was not completely prevented or reversed by early ART initiation, implying that damage to other cells in addition to CD4 T cells in the gut is needed to lead to a significant augmentation of bacterial translocation.

4.2. Targeting Gut Microbiota and Repairing the Breaches: Rebuilding Harmony {#s0095}
----------------------------------------------------------------------------

The combination of sulfasalazine, an anti-inflammatory molecule, and the antibiotic rifaximin, significantly reduced immune activation in SIV-infected pigtail macaques ([@bb0265]). However, long-term antibiotic therapies may result in the emergence of resistant microbes and in further injury to the gut barrier. Another therapeutic option that has been investigated in a fast-progressing, SIV-infected pigtailed macaque model, consists of neutralizing translocated gut microbial products using the LPS-binding drug sevelamer ([@bb0220]). This treatment was associated with reduction of SIV-induced inflammation, immune activation and coagulation markers, providing an important causal link between microbial translocation and deleterious immune activation. However, in individuals with untreated early HIV infection, sevelamer administration did not influence microbial translocation and inflammation, possibly reflecting low LPS translocation during this period of infection ([@bb0365]).

The use of ART highly effective in suppressing SIV replication in macaques has permitted the assessment of microbiota modulating strategies, involving probiotic bacteria and/or prebiotic nutrients. Remarkably, following treatment with a combination of probiotics, GI tract CD4 T cells were reconstituted in ART-treated, SIV-infected RMs ([@bb0210]). Moreover, administration of commensal *Lactobacillus plantarum* directly into the intestine of SIV-infected macaques led to the decreased secretion of IL-1β by Paneth cells, in addition to epithelial tight junction repair ([@bb0170]), suggesting that reduced inflammation is associated with gut barrier restoration. Encouragingly, probiotic/prebiotic therapies were also associated with immune benefits in ART-treated patients; however large, placebo-controlled clinical trials are necessary to assess the long-term efficacy of these therapies (reviewed in [@bb0050]). Finally, a more holistic picture may be required to treat SIV/HIV-induced gut damage given that certain microbes cohabit in a reciprocal relationship with parasitic helminths within the mammalian GI tract ([@bb0350]).

4.3. Immune-based Therapies for the Treatment of SIV/HIV-induced Gut Damage {#s0100}
---------------------------------------------------------------------------

Immune-based therapies designed to reduce intestinal inflammation and subsequent systemic immune activation have been investigated in RMs and in humans. While anti-TNF-α treatment successfully decreased the expression of proinflammatory genes and lowered the infiltration of PMNs into lymphoid tissues during early SIV infection, no change in viral load was reported ([@bb0410]), further arguing for the need to combine such anti-inflammatory strategies with ART. The common use of serum-derived bovine immunoglobulin to efficiently reduce intestinal inflammation in animal models was the rationale to implement a pilot clinical trial in ART-treated adults. These individuals experienced intestinal immune reconstitution and epithelial repair in the setting of HIV enteropathies ([@bb0020]). These early findings highlight the value of therapy designed to repair both immune and epithelial GI tract compartments.

The immune inhibitory receptor programmed death-1 (PD-1) regulates the functional exhaustion of virus-specific CD8 T cells during SIV/HIV infections ([@bb0415]). PD-1 blockade in SIV-infected RMs resulted in a lower plasma viral load and in reduced expression of transcripts associated with IFN signaling in the blood and colorectal tissue ([@bb0120]). Furthermore, these findings were associated with enhanced expression of gut-junction associated genes in colorectal tissue along with lower plasma LPS levels, suggesting immune improvement of both SIV-specific and mucosal immunity. However, blocking the PD-1 pathway in SIV-infected macaques conducted by another group showed limited clinical benefit, generating the hypothesis that blocking a single inhibitory pathway may not be sufficient to control SIV/HIV-induced exhaustion (reviewed in [@bb0430]).

The success of metformin treatment in attenuating IBD severity and in regulating the Th17/Treg ratio in mice ([@bb0225]), along with its routine use in diabetic patients, has led to the design of a clinical trial that will assess whether metformin can reduce inflammation in HIV-infected individuals. To modulate the Th17/Treg ratio, IDO inhibitors such as 1-methyl-D-tryptophan were also administered to ART-treated, SIV-infected RMs; this treatment reduced plasma viral load only in macaques that did not receive any immunological benefit from ART ([@bb0040]). Therefore, more studies are required to determine whether such an approach may be beneficial for the treatment of HIV infection.

Given the significant changes that occur in the chemokine network and in cell migration within the gut mucosa following SIV infection, strategies that target the gut-homing α4β7 integrin expressed by T cells have been investigated in RMs ([@bb0065]). In this study, administration of an anti-α4β7 monoclonal antibody reduced SIV transmission and protected gut mucosal CD4 T cells from infection. Encouragingly, SIV transmission was also reduced by the use of the CCL20 chemokine inhibitor glycerol monolaurate ([@bb0245]).

Other immune-based treatments that have been investigated for the treatment of SIV/HIV-mediated gut damage involved common gamma chain cytokines such as IL-7 and IL-21. ART-treated, SIV-infected RMs that received IL-7 demonstrated increased numbers of peripheral CD4 T cells ([@bb0030]); a similar effect was observed in HIV-infected patients ([@bb0230]). This therapy was shown to trigger chemokine expression in intestinal tissues as well as chemokine receptors and α4β7 integrin expression by circulating cells, leading to massive T cell homing to the gut mucosa, and decreased colonic inflammation ([@bb0035], [@bb0095], [@bb0375]).

IL-21 is a pleiotropic cytokine that induces Th17 cell differentiation and that promotes CD8 T cell cytotoxic function. Pallikkuth et al. have shown that IL-21 treatment of SIV-infected RMs increased Th17 cell frequency and enhanced the cytotoxic function of total and SIV-specific CD8 T cells ([@bb0315]). Such immune improvements were associated with reduced microbial translocation and with a long lasting reduction in immune activation in the blood and in the rectum. Similar results were obtained in another study in which IL-21 and probiotics were concurrently administered to ART-treated, SIV-infected pigtailed macaques ([@bb0310]). Importantly, this treatment led to increased gut CD4 T cell frequencies without altering viral suppression by ART. Interestingly, a reduction in the size of the viral reservoir was detected in ART-treated RMs receiving IL-21 ([@bb0280]). Currently, IL-21 is being investigated as an immunomodulatory cytokine in cancer patients and in HIV-infected persons.

5. Conclusion {#s0105}
=============

SIV infection studies have contributed to a better understanding of the detrimental role of gut damage in HIV pathogenesis. HIV infection induces important damages in lymphoid, myeloid and stromal cell gut compartments, while causing dysbiosis of microbial communities. These significant pathological changes induce the loss of gut barrier integrity, creating an "immune scar" that persists during chronic infection and that contributes to microbial translocation and inflammation, while increasing the risk of non-AIDS morbidities. We believe that, in addition to early ART initiation, modulation of the microbiota with probiotics and repairing gut damage with immune-based therapies have produced promising results that warrant future investigations to control residual inflammation and reduce viral reservoirs in persons living with HIV.

6. Outstanding Questions {#s0110}
========================

The proficient development of therapies for reversing gut damage in HIV-infected individuals will rely on the scientific and medical community to address major issues. First, the key to elucidate mechanisms of gut barrier integrity restoration may rely in our further understanding of the disparities between pathogenic and nonpathogenic SIV infections. Given the absence of microbial translocation in the latter, mucosal defense pathways are certainly preserved and more work is needed to assess the essential determinants for the persistence of gut integrity in a context of viral replication in natural hosts. Second, it becomes imperative to determine the role of the gut microbiota in HIV-induced gut damage and downstream inflammation. Future studies on gut microbial metabolites together with the development of metagenomic approaches may bridge the gap in our current knowledge, coupling gut microbiota composition, epithelial integrity and immune responses. On a clinical perspective, orchestrating the assessment of gut biopsies and their associated "local" microbiota as well as feces from large cohort of patients would certainly broaden our understanding of microbial-host interaction associated with epithelial and immune damage. Ultimately, a better characterization of the persistence of gut damage even after early ART initiation is warranted to identify the mechanisms responsible for this residual alteration. Although findings on antiretroviral pharmacodynamics in the GI tract were not discussed in this review, important data are missing in order to delineate whether incomplete gut epithelial restoration could be due to low drug concentration within this compartment. Notably, future studies should also address to what extent gut reconstitution is required for HIV-infected individuals to achieve full protection against co-morbidities.

7. Search Strategy and Selection Criteria {#s0005}
=========================================

We conducted a comprehensive literature review of English language publications in PubMed electronic database in which we searched for references for relevant articles; the search terms used were "acute SIV/HIV infections", "gut T cell", "innate lymphoid cells", "intestinal macrophages", "dendritic cells", "neutrophils", "epithelial damage", "microbiota", "microbial translocation", and "cytokine therapy". Except for seminal studies, only articles published between 2005 and 2015 were included.
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![Schematic representation of the multiple mechanisms that induce gut damage following SIV/HIV infections and strategies to reduce mucosal inflammation. Gut damage includes alterations to the microbiota, injuries to the gut epithelium, and changes to the immune mucosal landscape, all of which lead to persistent inflammation and systemic immune activation. Lymphoid cellular damage, which occurs in early infection, consists of CD4 T cell depletion, an altered Th17/Treg ratio, the loss of IL-17 producing innate lymphoid cells (ILCs), accumulation of CD8 T cells, and monocyte activation. These changes, which persist during disease progression, are accompanied by myeloid changes such as macrophage accumulation and defective phagocytosis, neutrophil and pDC infiltration, and the loss of CD103^+^ DCs. The loss of IL-17-producing CD8 T cells (Tc17 cells) also characterizes the chronic phase of infection. Overproduction of kynurenine (Kyn) metabolites from dietary tryptophan (Trp) by the immunosuppresive enzyme indoleamine 2,3-dioxygenase (IDO) contributes to an altered Th17/Treg ratio. Strategies to reduce mucosal inflammation are depicted in red.](gr1){#f0005}

###### 

Studies of intestinal CD4 T cell, CD8 T cell, and myeloid cell distribution during SIV infection of rhesus macaques.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gut segment           Methods   Time\                CD4 T cells                                         CD8 T cells                                      Myeloid cells                                References
                                  post-infection                                                                                                                                                         
  --------------------- --------- -------------------- --------------------------------------------------- ------------------------------------------------ -------------------------------------------- ----------------
  Jejunum               FC        Day 14 to 63         80--90% depletion of CD4^+^ CCR5^+^ T cells         NA                                               NA                                           [@bb0425]

  Rectum\               FC, IHC   Day 14               30% depletion\                                      NA                                               NA                                           [@bb0105] (Ch)
  \                                                    of LP CD4^+^ T cells\                                                                                                                             
  S.I.                                                 No depletion                                                                                                                                      

  Colon                 IHF       Day 14               50% depletion of\                                   NA                                               NA                                           [@bb0235]
                                                       CD4 T cells                                                                                                                                       

  Jejunum               FC        Chronic              Th17^+^ Th22^+^ depletion                           NA                                               NA                                           [@bb0455] (In)

  Jejunum               FC        Acute and chronic    CD4 T cell depletion                                NA                                               NA                                           [@bb9100]

  Jejunum,\             FC        Day 7\               30--50% depletion of\                               10--20% increase\                                NA                                           [@bb0420]
  ileum, colon                    \                    LP CD4^+^ CD25^+^ T cells\                          (jejunum and colon)\                                                                          
                                  \                    \                                                   \                                                                                             
                                  \                    80--90% depletion of\                               \                                                                                             
                                  Days 14, 21, 50      LP CD4^+^ CD25^+^ T cells                           10--50% increase\                                                                             
                                                                                                           (greatest in the ileum)                                                                       

  Jejunum               FC        Days 3, 7, 10, 14\   80% depletion of CD4^+^ CD45RA^−^ CCR5^+^ T cells   \                                                NA                                           [@bb0270]
                                  \                                                                        \                                                                                             
                                  Days 14, 17                                                              Increased frequency of total\                                                                 
                                                                                                           CD8 T cells                                                                                   

  Rectum\               FC\       Day 14 to week 6\    Decrease in CD4 Treg\                               Expansion of total CD8\                          NA                                           [@bb0295]
  \                     \         \                    \                                                   and CD8^+^ FOXP3^+^ T cells\                                                                  
  \                     \         \                    \                                                   \                                                                                             
  S.I., colon           FC        Chronic              NA                                                  Increased frequency of CD8^+^ FOXP3^+^ T cells                                                

  Colorectal biopsies   FC        Acute\               \                                                   Maintenance of Tc17 cells\                       NA                                           [@bb0300]
                                  Chronic              NA                                                  Loss of Tc17 cells                                                                            

  Jejunum               FC\       Day 21\              NA\                                                 Increase of ILC-17 cells\                        NA\                                          [@bb0460]
                        \         \                    \                                                   \                                                \                                            
                        \         \                    \                                                   \                                                \                                            
                        IHC       Chronic              NA                                                  Decreased numbers of Tc17\                       NA                                           
                                                                                                           and ILC-17 cells                                                                              

  Jejunum               FC        Day 8, 10\           Depletion of LP BrdU^+^ CD4 T cells                 \                                                NA                                           [@bb0450]
                                  \                                                                        \                                                                                             
                                  Day 13                                                                   Increased numbers\                                                                            
                                                                                                           of LPL BrdU^+^ CD8 T cells                                                                    

  Colon                 IHC       Chronic              NA                                                  NA                                               Neutrophil\                                  [@bb0140]\
                                                                                                                                                            infiltration (myeloperoxidase^+^)            (In)

  Colon                 FC        Chronic              Loss of Th17 cells                                  Decreased frequency of Tc17 cells                Loss of CD103^+^ DCs;\                       [@bb0205]
                                                                                                                                                            No change in the frequency of mDCs or pDCs   

  Colon, rectum         FC, IHF   Chronic              NA                                                  NA                                               4-fold increase in the\                      [@bb0345] (In)
                                                                                                                                                            number of CD123^+^ pDCs\                     
                                                                                                                                                            No change in the number\                     
                                                                                                                                                            of mDCs                                      

  Rectum                FC\       Day 14\              Decrease in\                                        NA                                               \                                            [@bb0315]
                        \         \                    CD4^+^ IL-17^+^ T cells                                                                              \                                            
                        IHC       Week 4                                                                                                                    Neutrophil infiltration\                     
                                                                                                                                                            (myeloperoxidase^+^)                         

  Ileum                 IHF       Days 3, 7, 10, 14    NA                                                  Increased numbers of LP CD8 T cells              Changes of macrophage counts\                [@bb0330] (Ch)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

S.I.: small intestine; FC: flow cytometry; IHC: immunohistochemistry; IHF: immunohistofluorescence; LP: lamina propria; DCs: dendritic cells; mDCs: myeloid-derived dendritic cells; pDCs: plasmacytoid dendritic cells; Tc17: IL-17 producing CD8 T cells; (Ch): rhesus macaque of Chinese origin and (In): rhesus macaque of Indian origin, when applicable; NA: not applicable. Studies are classified chronologically and according to the cell type.

###### 

Studies that assessed changes in immune-cell distribution in the gut of HIV-infected persons.

  Gut segment                       Methods   Estimated time post-infection   ART status                  Changes                                            References
  --------------------------------- --------- ------------------------------- --------------------------- -------------------------------------------------- ------------
  Rectum                            IHC       Early                           Naïve                       Decreased CD4/CD8 ratio                            [@bb0275]
  Duodenum                          FC        Chronic                         Naïve                       Increased number and frequency of Treg             [@bb0135]
  Rectum                            FC        Chronic                         Untreated                   Depletion of Th17 cells                            [@bb0380]
  Increased Treg frequency                                                                                                                                   
  Duodenum                          IHC       Chronic                         Naïve                       Accumulation of CD68^+^ and CD163^+^ macrophages   [@bb0005]
  Duodenum                          IHC       Hyper acute                     Naïve                       No depletion of CD4 T cells                        [@bb0010]
  Higher CD8 T cell numbers                                                                                                                                  
  Chronic                           Naïve     Depletion of CD4 T cells                                                                                       
  Increased number of CD8 T cells                                                                                                                            
  Accumulation of monocytes                                                                                                                                  
  Colon                             IHC       AIDS                            Naïve                       Accumulation of CD14^+^ macrophages                [@bb0080]
  Colorectal tissue                 IHC       Chronic                         ART-treated and untreated   Neutrophil infiltration                            [@bb0400]

IHC: immunohistochemistry; FC: flow cytometry; ART: antiretroviral therapy.

###### 

Studies of early changes in intestinal cytokine/chemokine networks in SIV-infected rhesus macaques.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gut segment       Time post-infection   Cytokine/chemokine          Change      Source                                                                                              References
  ----------------- --------------------- --------------------------- ----------- --------------------------------------------------------------------------------------------------- ----------------
  Small intestine   Acute                 CCL19 (MIP-3β), CXCL9       Increase    LPL[a](#tf0005){ref-type="table-fn"}                                                                [@bb0100]

  Jejunum           Day 21                Th1 and Th2 cytokines\      Decrease\   CD4 T cells[a](#tf0005){ref-type="table-fn"}\                                                       [@bb0190]
                                          IL-17, IFN-γ, GM-CSF, MIF   Increase    CD8 T cells[a](#tf0005){ref-type="table-fn"}                                                        

  Ileum             Day 2--3              IL-1β                       Increase    Paneth cells[a](#tf0005){ref-type="table-fn"}                                                       [@bb0170]

  Jejunum,\         Day 28                IL-10\                      Increase\   T cells, B cells, monocytes/macrophages, DCs, ECs[a](#tf0005){ref-type="table-fn"}\                 [@bb0320] (In)
  colon                                   \                           \           \                                                                                                   
                                          \                           \           T cells, B cells, monocytes/macrophages,\                                                           
                                          TNF-α\                      Increase\   NK, mast cells, endothelial cells, ECs[b](#tf0010){ref-type="table-fn"}\                            
                                          \                           \           \                                                                                                   
                                          \                           \           Th1 and CD8 T cells, B cells, macrophages, NKT, NK cells, DCs[b](#tf0010){ref-type="table-fn"}      
                                          IFN-γ                       Increase                                                                                                        

  Jejunum           Acute                 IFN-α\                      Increase\   Tcells, monocytes/macrophages, DCs, pDCs, NK cells, fibroblasts[b](#tf0010){ref-type="table-fn"}\   [@bb9100]
                                          \                           \           \                                                                                                   
                                          CXCL8 (IL-8)\               Increase\   T cells, monocytes/macrophages, endothelial cells, ECs[b](#tf0010){ref-type="table-fn"}\            
                                          \                           \           Monocytes/macrophages, DCs[b](#tf0010){ref-type="table-fn"}\                                        
                                          \                           \           Th17 cells, Th22 cells, ILCs[b](#tf0010){ref-type="table-fn"}\                                      
                                          IL-12\                      Increase\   Macrophages, DC                                                                                     
                                          \                           \                                                                                                               
                                          IL-17, IL-22\               Increase\                                                                                                       
                                          IL-23                       Increase                                                                                                        

  Small\            Days 3 to 10\         IL-7\                       Increase\   ECs[b](#tf0010){ref-type="table-fn"}\                                                               [@bb0330].\
  intestine         \                     \                           \           T cells[b](#tf0010){ref-type="table-fn"}\                                                           (Ch)
                    Days 7 to 14          CCL5 (RANTES)\              Increase\   ECs[b](#tf0010){ref-type="table-fn"}\                                                               
                                          \                           \           Monocytes/macrophages,\                                                                             
                                          CCL25 (TECK)\               Increase\   endothelial cells, fibroblasts[b](#tf0010){ref-type="table-fn"}                                     
                                          \                           \                                                                                                               
                                          CXCL10 (IP-10)              Increase                                                                                                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MIP-3β: macrophage inflammatory protein-3beta; LPL: lamina propria lymphocytes; IL: interleukin; IFN: interferon; GM-CSF: granulocyte macrophage colony stimulating factor; MIF: macrophage migration inhibitory factor; TNF: tumor necrosis factor; DCs: dendritic cells; ECs: epithelial cells; NK: natural killer; NKT: natural killer T cells; pDCs: plasmacytoïd dendritic cells; RANTES: regulated on activation, normal T cell expressed and secreted; TECK: thymus-expressed chemokine; IP-10: interferon gamma-induced protein 10.; (Ch): rhesus macaque of Chinese origin and (In): rhesus macaque of Indian origin, when applicable.

As indicated in the study

As indicated in the literature.
